JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan International Research Enhanced Equity ETF
JIRE
|
+$4.16B |
| 2 |
Microsoft
MSFT
|
+$2.29B |
| 3 |
Amazon
AMZN
|
+$2B |
| 4 |
UnitedHealth
UNH
|
+$1.76B |
| 5 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.42B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.61B |
| 2 |
Vanguard Short-Term Bond ETF
BSV
|
+$1.58B |
| 3 |
State Street Financial Select Sector SPDR ETF
XLF
|
+$689M |
| 4 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$659M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$647M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.28% |
| 2 | Technology | 15.04% |
| 3 | Healthcare | 12.52% |
| 4 | Financials | 10.55% |
| 5 | Consumer Discretionary | 7.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
SHCR
4776
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $230K | ﹤0.01% |
145,344
+26,765
| +23% | +$65.7K |
2021 Q3
3 quarters
|
|
|
PSTH
4777
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
| $230K | ﹤0.01% |
11,500
-157,886
| -93% | -$3.14M |
2020 Q3
7 quarters
|
|
4778
Colony Bankcorp
CBAN
$431M
| $229K | ﹤0.01% |
15,168
+5,162
| +52% | +$86.1K |
2019 Q1
13 quarters
|
|
4779
Stagwell
STGW
$2.07B
| $229K | ﹤0.01% |
42,046
+12,773
| +44% | +$90.5K |
2021 Q2
4 quarters
|
|
4780
CALL
Teck Resources
TECK
$32B
| $229K | ﹤0.01% |
7,500
-632,500
| -99% | -$25M |
2022 Q1
1 quarter
|
|
4781
Upland Software
UPLD
$10.7M
| $229K | ﹤0.01% |
1,575
+206
| +15% | +$30.1K |
2017 Q2
20 quarters
|
|
4782
First Business Financial Services
FBIZ
$582M
| $227K | ﹤0.01% |
7,263
+600
| +9% | +$20K |
2021 Q4
2 quarters
|
|
4783
Erasca
ERAS
$5.1B
| $225K | ﹤0.01% |
40,322
-9,892
| -20% | -$64.7K |
2021 Q3
3 quarters
|
|
4784
GDS Holdings
GDS
$5.97B
| $225K | ﹤0.01% |
6,733
-163,242
| -96% | -$5.07M |
2017 Q1
21 quarters
|
|
|
DNMR
4785
DELISTED
Danimer Scientific, Inc.
DNMR
| $225K | ﹤0.01% |
1,231
-451
| -27% | -$81.9K |
2021 Q1
5 quarters
|
|
4786
Hingham Institution for Saving
HIFS
$624M
| $224K | ﹤0.01% |
787
-417
| -35% | -$131K |
2016 Q3
23 quarters
|
|
4787
Stratasys
SSYS
$747M
| $224K | ﹤0.01% |
+11,928
| New | +$235K |
2022 Q2
0 quarters
|
|
4788
Tango Therapeutics
TNGX
$4.12B
| $224K | ﹤0.01% |
49,327
+23,090
| +88% | +$140K |
2021 Q3
3 quarters
|
|
4789
Esquire Financial Holdings
ESQ
$1.43B
| $223K | ﹤0.01% |
6,702
+4,879
| +268% | +$172K |
2018 Q2
16 quarters
|
|
4790
James Hardie Industries
JHX
$14.6B
| $223K | ﹤0.01% |
10,186
+7,260
| +248% | +$192K |
2015 Q1
29 quarters
|
|
|
VLD
4791
DELISTED
Velo3D, Inc.
VLD
| $222K | ﹤0.01% |
4,585
+4,098
| +841% | +$479K |
2021 Q3
3 quarters
|
|
|
KNTE
4792
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $221K | ﹤0.01% |
17,507
-4,363
| -20% | -$40.6K |
2021 Q1
5 quarters
|
|
4793
dLocal
DLO
$4.04B
| $220K | ﹤0.01% |
8,382
+1,087
| +15% | +$27.8K |
2022 Q1
1 quarter
|
|
4794
FRP Holdings
FRPH
$393M
| $220K | ﹤0.01% |
7,288
+898
| +14% | +$26.2K |
2017 Q4
18 quarters
|
|
4795
MiMedx Group
MDXG
$677M
| $219K | ﹤0.01% |
63,309
-14,909
| -19% | -$58.4K |
2020 Q4
6 quarters
|
|
|
EGIO
4796
DELISTED
Edgio, Inc. Common Stock
EGIO
| $219K | ﹤0.01% |
2,371
+294
| +14% | +$42.3K |
2016 Q4
22 quarters
|
|
4797
Anika Therapeutics
ANIK
$259M
| $218K | ﹤0.01% |
9,750
+1,198
| +14% | +$26.7K |
2015 Q4
26 quarters
|
|
|
RNLX
4798
DELISTED
Renalytix plc American Depositary Shares
RNLX
| $218K | ﹤0.01% |
88,410
+43,724
| +98% | +$208K |
2021 Q1
5 quarters
|
|
|
TCDA
4799
CALL
DELISTED
Tricida, Inc. Common Stock
TCDA
| $218K | ﹤0.01% |
+22,500
| New | +$214K |
2022 Q2
0 quarters
|
|
4800
Bionano Genomics
BNGO
$18.5M
| $217K | ﹤0.01% |
262
-104
| -28% | -$107K |
2021 Q2
4 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2022 Portfolio in Review
As of Q2 2022, JP Morgan Chase held 7,270 positions worth $718B, down 14% from $830B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2022 filing shows 568 new, 2,561 increased, 2,728 reduced and 609 closed positions. Its largest new stake was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B. The largest sale was JPMorgan BetaBuilders Europe ETF, an estimated $4.61B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Healthcare.
- JP Morgan Chase's largest Q2 2022 buy was JPMorgan International Research Enhanced Equity ETF: 85,906,762 shares worth $4.15B.
- JP Morgan Chase added most to Microsoft in Q2 2022, an estimated $2.29B increase.
- JP Morgan Chase's biggest Q2 2022 reduction was JPMorgan BetaBuilders Europe ETF, cutting an estimated $4.61B.
- JP Morgan Chase fully exited Cerner Corp in Q2 2022, selling an estimated $608M.
- JP Morgan Chase's ten largest holdings make up 18% of its $718B portfolio in Q2 2022.
- JP Morgan Chase opened 568 new positions and closed 609 in Q2 2022.
- JP Morgan Chase's portfolio value fell 14% quarter-over-quarter to $718B.
Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.